NEILMED HOLDING COMPANY LIMITEDActive

Company number 10246838Private limited companyIncorporated 2016

Key figures

£70,501-94.1%
Net assets 2025
-49.8%
Average annual change 2020–2025
0500 k1 m1.5 m20202021202320242025

Like most small UK companies, NEILMED HOLDING COMPANY LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2025
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
0500 k1 m1.5 m20202021202320242025
Filed accounts2020–2025
20202021202320242025
Turnover——0——
Profit for the year——-44,803——
Cash at bank and in hand9,40726,50617,5423,164603
Total assets1,096,4541,086,5451,175,1551,206,359734,636
Total liabilities—————
Net assets / total equity1,106,9301,058,7511,179,0211,195,78470,501
Average number of employees222802712

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Principal activity

Accounts 2025

sale of pharmaceutical products and investments in subsidiaries.

As described in the company's latest filed accounts.

Summary: NEILMED HOLDING COMPANY LIMITED

Company

NEILMED HOLDING COMPANY LIMITED is a private limited company registered with Companies House under company number 10246838. It was incorporated on 23 Jun 2016. Its status is active. The registered office is in Harrow (HA3). Its nature of business (SIC 2007) is wholesale of pharmaceutical goods (46460).

Accounts

The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files group accounts. Net assets were £70,501, down 94.1% on the previous year. Cash at bank and in hand was £603. The company had an average of 12 employees. Figures are available for 5 financial years (2020–2025).

Control and charges

One person with significant control is registered.

Filing deadlines

The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 28 Nov 2026.